Prime Highlights-
- Hikma revenue grows 4 percent to $1.728 billion, core operating profit rises 9 percent.
- Branded business grows 15 percent, expected to reach top end of guidance range.
Key Facts-
- Hikma delivers 48 product submissions, 43 launches, ten new MENA partnerships in H1.
- Tobias Hestler joins board as independent Non-Executive Director from FTSE 100 background.
Background-
Hikma Pharmaceuticals turned in strong results for the first half through June 2026, with revenue advancing 4 percent to $1.728 billion on robust growth in its Branded business.
Chief Executive Said Darwazah said the results matched expectations, citing 9 percent growth in core operating profit and positive momentum across the organisation, supported by new product launches, a strengthened pipeline, fresh partnerships, and improved manufacturing operations.
The company’s $250 million share buyback continues progressing well, while regional teams drive commercial gains across North America, Europe, and MENA. Hikma delivered 48 product submissions and 43 launches in the first half, alongside ten new MENA partnerships.
Hikma remains the largest pharmaceutical company in MENA by sales, the seventh largest generic medicine supplier in the US, and the fourth largest injectables supplier by sales in Europe.
The Branded business grew 15 percent, led by strong performances in Saudi Arabia and in chronic illness treatments including diabetes and cardiovascular products.
Fourteen of 15 new launches across major markets ranked as first-to-market or first-generic. Branded revenue is now expected to reach the top end of the 6 to 8 percent guidance range.
Injectables performed in line with expectations, supported by steady US demand and new launches across Europe and MENA. Hikma Rx posted strong growth in operating profit, and contract manufacturing picked up momentum on the back of higher revenue and improved margins.
Hikma also appointed Tobias Hestler, a former FTSE 100 chief financial officer, as independent Non-Executive Director, and reiterated full year revenue guidance of 2 to 4 percent growth in constant currency.
